A carregar...
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis
BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor which blocks cytokine signaling involved in the pathogenesis of autoimmune diseases including ulcerative colitis (UC). The etiology of UC is poorly understood, however research suggests the development and progression of the disease is...
Na minha lista:
| Publicado no: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2020
|
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6984444/ https://ncbi.nlm.nih.gov/pubmed/31984480 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012381.pub2 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|